This could SRPT as not only the drug of choice between the two which we already knew but it may be the only drug available. SRPT may not have to deal with Prosensa with a competitor and now that could push the FDA into granting AA because Prosensa's drug may not be something available as well. I wonder how this will affect the availability of Eteplirsen in Europe. Maybe GSK works out the patent issue with SRPT?
This would make parnerships a whole lot easier if SRPT is the only game in town in Europe. Prosensa would be very willing to make a deal under this scenerio. Their both exon skippers but different chemistries are the key.
Glaxo disclosing this may mean they're ready to deal with us on the EU exon51 patent. It may also mean Prosensa - being stuck with this backbone that's causing the damage - has lousy chemistry behind all their pretty good looking patents. It may be time for Sarepta to start thinking again about that European branch and a merger with Prosensa.
I wonder if GSK would come crawling to SRPT in hopes of partnering? Why would GSK want to spend millions and millions trying to sell a drug that appears to be completely inferior to Eteplirsen. Seems like a waste of money.